Imagion Biosystems Limited
ASX: IBX.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Robert Romeo Proulx
- Employees
- 11
- Headquarters
- San Diego, United States
- IPO year
- 2017
- Market cap
- A$3.3M
- Website
- https://imagionbiosystems.com
Loading IBX…
Loading profile data…Frequently asked questions about IBX
What does Imagion Biosystems Limited (IBX.AX) do?
Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the tre...
Where does IBX.AX trade?
Imagion Biosystems Limited (IBX.AX) trades on the Australian Securities Exchange.
What sector is IBX.AX in?
Imagion Biosystems Limited (IBX.AX) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Imagion Biosystems Limited?
Robert Romeo Proulx is the chief executive officer of Imagion Biosystems Limited (IBX.AX).
Where is Imagion Biosystems Limited headquartered?
Imagion Biosystems Limited is headquartered in United States.
Does IBX.AX pay a dividend?
Imagion Biosystems Limited (IBX.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IBX.AX go public?
Imagion Biosystems Limited (IBX.AX) completed its initial public offering in 2017.